Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

21.12 -0.03 (-0.14%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharm Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product
Shares have sat atop the IBD 50 for weeks, have perfect ratings and recently hit a profit-taking zone. 
Via Investor's Business Daily
Why Catalyst Pharmaceuticals Shares Are Moving
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 13.46% to $18.00 Monday morning after Teva Pharmaceuticals stated it plans to sell a generic version of Catalyst's FIRDAPSE in... 
Via Benzinga
Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Analyst Expectations for Catalyst Pharmaceuticals's Future
Via Benzinga
2 Biotechs Making Waves With A Single Product in their Pipeline
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise. 
Via MarketBeat
HC Wainwright & Co. Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
IDEXX Laboratories Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
IDEXX Laboratories sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
Top Picks For 2023: Catalyst Pharmaceuticals - Sunday, Jan. 8
For a growth-oriented choice for the new year, I'm going with under-the-radar company, Catalyst Pharmaceuticals. Let's take a look at the company's fundamentals, technicals, and institutional support... 
Via Talk Markets
Top Picks For 2023: Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top... 
Via Talk Markets
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
Via Benzinga
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
This Growth Stock's Jaw-Dropping Run-Up Is Smashing Tesla's
It's practically printing cash, and even more is on the way. 
Via The Motley Fool
Moderna Stock Shows Surprising Strength; Key Rating Upgraded
See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average. 
Via Investor's Business Daily
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier. 
Via Investor's Business Daily
Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Stock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review
Bitcoin hit a two-year low while Meta and Tesla were in focus. 
Via Investor's Business Daily
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
Catalyst Pharma, The No. 1 IBD 50 Stock, Just Trounced Third-Quarter Expectations
The company sells one drug, a treat for a rare muscle contraction condition. 
Via Investor's Business Daily
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Can Mid-Cap Lantheus Continue its 2022 Outperformance?
Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test. 
Via MarketBeat
Topics ETFs Initial Public Offering
Exposures Securities Market
Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
These 3 Stocks Are Winning the Bear Market -- Here's How
Picking the right markets to compete in makes surviving bear markets much more manageable for these companies. 
Via The Motley Fool
Amgen Stock Shows Market Leadership With Jump To 90 RS Rating
On Wednesday, Amgen stock hit a key technical milestone, with its Relative Strength Rating upgraded to 90, a rise from 78 the day before. 
Via Investor's Business Daily
BioCryst Pharmaceuticals Stock Shows Rising Relative Strength
On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93. 
Via Investor's Business Daily
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients
FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S. 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Intercept Pharmaceutical Stock Sees RS Rating Rise To 91
Intercept Pharmaceutical shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating
Pain Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.